Images List Premium Download Classic

Psychiatric Disorders

Psychiatric Disorders-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
H. Lundbeck A/s
January 04, 2018 - N°20180000786

The present invention provides 1h-pyrazolo[4,3-b]pyridin-7-amines of formula (i) as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
Neurovance, Inc.
January 04, 2018 - N°20180000777

The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3. 1. 0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (cns) disorders, including depression and anxiety.
Positive allosteric modulators of the muscarinic acetylcholine receptor m4
Vanderbilt University
December 28, 2017 - N°20170369505

Disclosed herein are tricyclic compounds, including pyrimido[4′,5′:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2′,3′:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3′,2′:4,5]furo[3, 2-d]pyrimidin-4-amine, and pyrimido[4′,5′:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4). Also ...
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Ethyldiamine orexin receptor antagonists
Merck Sharp & Dohme Corp.
December 14, 2017 - N°20170355692

The present invention is directed to ethyldiamne compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention ...
Pyrrolidine orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 30, 2017 - N°20170342052

The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention ...
Magnetic field stimulation
The Mclean Hospital Corporation
November 30, 2017 - N°20170340894

A magnetic coil system featuring a multi-layer structure, a spherical shape, or both allows for efficient generation of a gradient magnetic field that induces an electric field in air in a region proximate to the coil. By subjecting at least a portion of a person's brain to the induced electric field various psychiatric disorders can be treated.
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and ...
November 23, 2017 - N°20170333426

Wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mglur2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mglur2 subtype of metabotropic receptors is involved. The ...
Piperidine isoxazole and isothiazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 16, 2017 - N°20170327490

The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these ...
Methods for treating psychiatric disorders
November 16, 2017 - N°20170326356

Methods for treating subjects afflicted with a psychiatric disorders [e. G., autism spectrum disorder (asd), schizophrenia, and/or depression] are described herein. More particularly, the present invention relates to a method for treating a subject afflicted with or at risk for developing a psychiatric disorder (e. G., asd, of which autism is a particular example) that calls for selecting a ...
Composition and method for treatment of neuropsychiatric disorders
Duke University
November 16, 2017 - N°20170326127

The present invention relates to a composition and method for combinative therapy, capable of temporarily regulating inherent dysfunctional neural processes and reducing symptoms and/or signs of neuropsychiatric disorders including, but not limited to, psychostimulant use disorder (pud) and other substance-related additive disorders, post-traumatic stress disorder (ptsd) and other trauma- and stress-related disorders, and levodopa-induced dyskinesia (lid) and other types ...
Hydroxmethyl piperidine orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320884

The present invention is directed to hydroxymethyl piperidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Bridged diazepane orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320876

The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320874

The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Psychiatric Disorders Patent Pack
Download + patent application PDFs
Psychiatric Disorders Patent Applications
Download + Psychiatric Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Psychiatric Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Amidoethyl azole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320856

The present invention is directed to amidoethyl azole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Pyrazole, triazole and tetrazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170319560

The present invention is directed to pyrazole, triazole and tetrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole, triazole, and tetrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to ...
Piperidine oxadiazole and thiadiazole orexin receptor antagonists
November 02, 2017 - N°20170313693

The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these ...
Pyrazole orexin receptor antagonists
November 02, 2017 - N°20170313684

The present invention is directed to pyrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The ...
Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
November 02, 2017 - N°20170312308

The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (ptsd) in subjects, e. G., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat ...
Systems and methods for generating biomarkers based on multivariate classification of functional imaging and associated ...
The Brigham And Women's Hospital, Inc.
October 26, 2017 - N°20170309022

Systems and methods for generating biomarkers associated with neuropsychiatric disorders, neurodevelopmental disorders, neurobehavioral disorders, or other neurological disorders are described. In general, the biomarkers are generated based on correlations between functional imaging data and clinical acquired from a subject, as computed using a multivariate classifier. Functional imaging data may include functional magnetic resonance images, or activation maps generated from such ...
Methyl diazepane orexin receptor antagonists
Merck Sharp & Dohme Corp.
October 26, 2017 - N°20170305916

The present invention is directed to methyl diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors
Domain Therapeutics
October 26, 2017 - N°20170305913

The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (i) and pharmaceutical compositions containing them. Moreover, the compounds of formula (i) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate ...
Loading